Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 107Specimen Handling 78Magnetic Resonance Spectroscopy 69Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 49Cyclophosphamide 49Paclitaxel 48durvalumab 37Gemcitabine 37Radiation 36Dexamethasone 32olaparib 31Etoposide 31Rituximab 30Docetaxel 30Doxorubicin 28atezolizumab 27Ipilimumab 27Lenalidomide 26Taxes 25Pemetrexed 24Bevacizumab 24Vincristine 23Platinum 23Cytarabine 23Radiotherapy, Intensity-Modulated 22Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × lorlatinib × 90 days × Clear all
NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Pfizer

Completed
73 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡